Date: 2015-09-23
Type of information: Nomination
Compound:
Company: NeRRe Therapeutics (UK)
Therapeutic area:
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On September 23, 2015, NeRRe Therapeutics, a clinical stage company developing a portfolio of neurokinin receptor antagonists, announced that Dr Mary Kerr1 is joining the company as CEO at the beginning of October. Mary Kerr1 has spent the majority of her career on the R&D/commercial interface in global strategy and regional operational roles at the pharmaceutical company GSK and predecessor companies, predominantly in the speciality and orphan drug areas. She has also been appointed an Operating Partner at Advent Life Sciences, one of NeRRe’s investors.
- Prior to her appointment at NeRRe, Mary held a range of senior leadership roles for more than 20 years, most recently as Senior Vice President and Global Franchise Leader for GSK’s Immunoinflammation and Infectious Diseases portfolio. Before that she was a founding member in the executive team of ViiV Healthcare, the independent, HIV company that combines the HIV expertise of GSK, Pfizer Inc and Shionogi, where she led, revitalised and grew the business in Europe.
- NeRRe Therapeutics was formed in December 2012 and is focussed on the development of a portfolio of NK receptor antagonists acquired from GSK, which have therapeutic potential in a broad range of indications. The company has intimate knowledge of the transferred assets and the neurokinin receptor system field. In 2012 NeRRe Therapeutics raised £11.5 million ($18.4 million) in Series A financing from two Novo A/S and Advent Life Sciences, who are represented by Dr Martin Edwards (Chairman) and Dr Kaasim Mahmood respectively on the company’s Board. NeRRe is based at Stevenage Bioscience Catalyst campus.
Financial terms:
Latest news:
Is general: Yes
